Last reviewed · How we verify
Meclofenamate
At a glance
| Generic name | Meclofenamate |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Target | Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Dysmenorrhea
- Menorrhagia
- Osteoarthritis
- Pain
- Rheumatoid arthritis
Common side effects
- Diarrhea
- Nausea with or without vomiting
- Other gastrointestinal disorders
- Abdominal pain
- Pyrosis
- Flatulence
- Anorexia
- Constipation
- Stomatitis
- Peptic ulcer
- Edema
- Rash
Key clinical trials
- Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary (NA)
- Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meclofenamate CI brief — competitive landscape report
- Meclofenamate updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI